Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

Autores

  • Bruno Coêlho Cavalcanti Centro Universitário Christus
  • Cecília Rocha da Silva Federal University of Ceará
  • João Batista de Andrade Neto Federal University of Ceará
  • Maria Aparecida Alexandre Josino Federal University of Ceará
  • Lívia Gurgel do Amaral Valente Sá Federal University of Ceará
  • Antônio Adailson de Sousa Silva Federal University of Ceará
  • Francisco Stefânio Barreto Federal University of Ceará
  • José Roberto de Oliveira Ferreira
  • Hemerson Iury Ferreira Magalhães Federal University of Ceará
  • Ícaro Gusmão Pinto Vieira Federal University of Ceará
  • Débora Hellen Almeida Brito Federal University of Ceará
  • Nágila Maria Pontes Silva Ricardo Federal University of Ceará
  • Fátima Daiana Dias Barroso Federal University of Ceará
  • Érica Rayanne Mota da Costa Federal University of Ceará
  • Hélio Vitoriano Nobre Júnior Federal University of Ceará
  • Manoel Odorico de Moraes Federal University of Ceará

DOI:

https://doi.org/10.12662/2317-3076jhbs.v10i1.4461.p1-6.2022

Palavras-chave:

Fluoxetine, Galactomannan, Mutagenicity, Chromosomal aberrations, Salmonella typhimurium /microsome assay

Resumo

Objectives: The purpose of this study was to evaluate the mutagenic potential of fluoxetine and fluoxetine-galactomannan. Methods: Chromosomal aberration test and Salmonella typhimurium/microsome mutagenicity assay. Results: The results showed that fluoxetine (250 μg/mL) can cause chromosomal breaks of treated leukocytes and increase the frequency of reversion of the tester strains of S. typhimurium / microsome assay only at the highest concentration (5 mg/mL), while fluoxetine encapsulated in galactomannan did not cause these changes (leukocytes and S. typhimuriums strains). Conclusion: In summary, fluoxetine showed a mutagenic effect detectable only at high concentrations in both eukaryotic and prokaryotic models. Furthermore, the fluoxetine/galactomannan complex, in this first moment, prevented the mutagenicity attributed to fluoxetine, emphasizing that the present encapsulation process can be an alternative in preventing these effects in vitro.

Downloads

Não há dados estatísticos.

Publicado

2022-12-01